News

New drugs are now in the pipeline to focus on treatment of the disease.

According to the company, its ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver the world's first femtosecond laser image-guided high-precision trabeculotomy.

Patients who have signs or symptoms of an eye infection after using these products should talk to their health care provider or seek medical care immediately.

With the combined system, surgeons will also save space in the operating room and optimize cataract surgery all on one system.

Acanthamoeba keratitis can lead to inflammation of the cornea and result in extreme levels of pain, light sensitivity and vision loss.

Prevent Blindness is offering videos, fact sheets, social media graphics and PowerPoint presentations to educate the public on the potential effects diabetes may have on vision.

Transparent pricing in elective surgeries is crucial.

When patients pay for elective procedures, premium experience often falters.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

BRIO-1 clinical trial sowing optimism as a potential therapeutic option.

Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.

Huang and 2 OCT co-inventors were honored this week at the White House with the National Medal of Technology and Innovation.

The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.

Technology allows partitioning of sequencing reads into 2 parental genome data sets.

According to the company, the software is designed to streamline the flow of information, surgical planning, and enable electronic medical record and diagnostic device integration.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

According to the company, the clinical trial will assess the safety, efficacy and tolerability of AURN001, a combination cell therapy product.

Physician discusses 5 keys to achieve optimal results for patients

According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.

The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.

According to a lawsuit filed in U.S. District Court in Detroit, a policy requires Henry Ford Health and Henry Ford Medical Group (HFMG) employees to undergo a screening assessment for cognition when they reach the age of 70, again at age 75 and each year after that.

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

Developing technology may offer marked improvements in surgical precision

The FDA has granted temporary discretion to import erythromycin ophthalmic ointment for the treatment of newborns.

Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

According to a human study of older adults, grape intake improved macular pigment accumulation and downregulated harmful biomarkers.